An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

NCT01381809 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Group 2: Placebo
DRUG: Group 1: Epoetin alfa

Sponsor

Janssen-Cilag International NV